Role of curcumin in the prevention of cholinergic mediated cortical dysfunctions in streptozotocin-induced diabetic rats.
Diabetes exacerbates neuronal injury mediated through neurotransmitters deregulation in cerebral cortex. Our study analyzed the neuroprotective effect of curcumin to prevent cortical dysfunction associated with diabetes. Our study revealed decreased gene expression of muscarinic M1, insulin receptor, SOD, choline acetyl transferase and increased gene expression of muscarinic M3, α7-nicotinic acetylcholine receptor, acetylcholine esterase and GLUT3 in cerebral cortex of diabetic rats. Curcumin and insulin treatment reversed this altered parameters to near control. Immunohistochemistry studies of muscarinic M1 and M3 confirmed the gene expression at protein level. Decreased novel arm entry of diabetic rats in Y-maze test, improved in treatment group. These results suggest that cholinergic dysfunction, impaired glucose transport and oxidative stress contributes to learning and memory deficits in diabetes and further suggest that antioxidant curcumin has potential therapeutic role in preventing and/or delaying the diabetic complications associated with brain.
Peeyush Kumar
T
T
Molecular Neurobiology and Cell Biology Unit, Centre for Neuroscience, Cochin University of Science and Technology, Cochin 682022, Kerala, India.
Antony
Sherin
S
Soman
Smijin
S
Kuruvilla
Korah P
KP
George
Naijil
N
Paulose
C S
CS
D000110:Acetylcholinesterase / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000378:metabolism; D001285:Atropine / Q000378:metabolism; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects* / Q000503:physiopathology*; D002795:Choline O-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D003474:Curcumin / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology* / Q000517:prevention & control*; D004158:Diphenylacetic Acids / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D051274:Glucose Transporter Type 3 / Q000235:genetics / Q000378:metabolism; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D010880:Piperidines / Q000378:metabolism; D010890:Pirenzepine / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011972:Receptor, Insulin / Q000235:genetics / Q000378:metabolism; D043643:Receptor, Muscarinic M1 / Q000235:genetics / Q000378:metabolism; D043587:Receptor, Muscarinic M3 / Q000235:genetics / Q000378:metabolism; D011950:Receptors, Cholinergic / Q000378:metabolism*; D011978:Receptors, Nicotinic / Q000235:genetics / Q000378:metabolism; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism; D064569:alpha7 Nicotinic Acetylcholine Receptor
D000906:Antibodies; C579165:Chrna7 protein, rat; D004158:Diphenylacetic Acids; D051274:Glucose Transporter Type 3; D010880:Piperidines; D043643:Receptor, Muscarinic M1; D043587:Receptor, Muscarinic M3; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; C074183:N-(2-chloroethyl)-4-piperidinyl diphenylacetate; D010890:Pirenzepine; D001285:Atropine; D013482:Superoxide Dismutase; D002795:Choline O-Acetyltransferase; D011972:Receptor, Insulin; D000110:Acetylcholinesterase; D003474:Curcumin